Brinsupri (brensocatib) is a prescription oral medication used to treat non-cystic fibrosis bronchiectasis, often shortened to NCFB, in adults and children 12 years of age and older. If bronchiectasis were a messy kitchen, mucus would be the sticky spill, inflammation would be the smoke alarm, and flare-ups would be the moment everyone suddenly realizes nobody cleaned the stove. Brinsupri is designed to help reduce those flare-ups by targeting a specific inflammation pathway rather than simply chasing symptoms after they appear.
This article explains Brinsupri uses, dosing, side effects, drug interactions, warnings, tablet pictures and identification, and practical patient-experience considerations in plain American English. It is for educational purposes only and should not replace medical advice from a licensed healthcare professional.
What Is Brinsupri?
Brinsupri is the brand name for brensocatib, a medicine classified as a dipeptidyl peptidase 1 inhibitor, or DPP1 inhibitor. It is taken by mouth as a tablet once daily. Unlike an antibiotic, it does not directly kill bacteria. Unlike a rescue inhaler, it does not provide quick relief during sudden breathing trouble. Instead, Brinsupri works on a deeper inflammatory process involved in bronchiectasis flare-ups.
NCFB is a chronic lung condition in which the airways become damaged and widened over time. That widening makes it harder to clear mucus, which can lead to repeated infections, coughing, thick sputum, shortness of breath, fatigue, and exacerbations. A flare-up can feel like the lungs have decided to host a very rude surprise party: more coughing, more mucus, more breathlessness, and often a need for antibiotics or medical care.
What Is Brinsupri Used For?
Brinsupri is used for the treatment of non-cystic fibrosis bronchiectasis in adults and pediatric patients 12 years and older. It is not approved for children under 12 years old, and it is not the same as treatment for cystic fibrosis-related bronchiectasis.
Main Approved Use
The main approved use of Brinsupri is to help manage NCFB by reducing pulmonary exacerbations, also called flares. In clinical studies, people taking Brinsupri had fewer bronchiectasis exacerbations than those taking placebo. This matters because repeated flares can disrupt school, work, sleep, exercise, and general quality of life. More importantly, frequent exacerbations may contribute to worsening lung function over time.
What Brinsupri Does Not Do
Brinsupri is not a cure for bronchiectasis. It does not replace airway clearance, vaccines recommended by a clinician, infection monitoring, inhaled therapies, pulmonary rehabilitation, or antibiotics when those are needed. Think of it as one member of the treatment team, not the entire marching band.
How Brinsupri Works
Brinsupri blocks DPP1, an enzyme involved in activating inflammatory proteins called neutrophil serine proteases. These include neutrophil elastase, cathepsin G, and proteinase 3. In bronchiectasis, overactive neutrophil-driven inflammation can damage the airways and help fuel the cycle of mucus buildup, infection, irritation, and flare-ups.
By inhibiting DPP1, brensocatib helps reduce the activation of these inflammatory enzymes. In everyday language, it tells part of the immune system’s “demolition crew” to stop swinging the hammer so enthusiastically inside already-irritated airways.
Brinsupri Dosing: How It Is Taken
The labeled Brinsupri dosage is 10 mg or 25 mg by mouth once daily, with or without food. A healthcare provider decides which strength is appropriate based on the patient’s medical situation. Patients should not change the dose on their own.
General Dosing Tips
- Take Brinsupri once daily, around the same time each day.
- It may be taken with food or without food.
- Do not take extra tablets to “catch up.” Lungs appreciate consistency, not surprise math.
- Keep regular appointments so the prescriber can monitor benefits and side effects.
Missed Dose
If a dose is missed, patients should follow the instructions from their prescriber and the official patient information. The prescribing information advises taking the next dose at the regular time the next day and not doubling the dose to make up for a missed tablet.
Storage
Brinsupri should be stored at room temperature in its original container, away from excess heat and moisture. It should be kept out of reach of children and pets. The bathroom medicine cabinet may be convenient, but humidity makes it a questionable real estate choice for many medications.
Brinsupri Pictures and Tablet Identification
Brinsupri comes as film-coated tablets in two strengths:
- Brinsupri 10 mg: brown, round, film-coated tablet, debossed with “10” on one side and “BRE” on the other.
- Brinsupri 25 mg: gray, round, film-coated tablet, debossed with “25” on one side and “BRE” on the other.
Tablet appearance can help confirm the medication, but it should not be the only method of identification. If a tablet looks different, is chipped, has changed color, came from an unmarked container, or seems suspicious, ask a pharmacist before taking it. When it comes to prescription medicine, guessing is not a personality trait worth developing.
Common Side Effects of Brinsupri
Like all medications, Brinsupri can cause side effects. Not everyone gets them, and some side effects may be mild. Still, knowing what to watch for can help patients communicate clearly with their healthcare team.
Commonly Reported Side Effects
- Upper respiratory tract infection symptoms, such as cough, runny nose, or sore throat
- Headache
- Rash
- Dry skin or chapped lips
- Hyperkeratosis, meaning thickened areas of skin
- High blood pressure
- Hair loss, reported less commonly in patient-facing drug information
In clinical trial data, upper respiratory tract infections and headache were among the most frequent adverse reactions. Skin-related effects such as rash, dryness, peeling, fissures, or thickened skin are especially important because Brinsupri’s label includes warnings about dermatologic reactions.
Serious Side Effects and When to Call a Doctor
Patients should contact a healthcare professional promptly if they notice a new or worsening rash, dry or peeling skin, thickened skin patches, painful mouth symptoms, gum swelling, bleeding gums, loose teeth, tooth pain, or signs of infection. Medical help is also important for severe allergic-type symptoms, breathing difficulty, chest pain, fainting, or any sudden concerning reaction.
Skin Concerns
Brinsupri is associated with increased dermatologic reactions, including rash, dry skin, and hyperkeratosis. Patients may be advised to monitor their skin and may need evaluation by a dermatologist for new findings. A practical approach is to pay attention to changes after starting therapy instead of brushing them off as “just winter skin,” especially if it is not winter.
Gum and Dental Concerns
Brinsupri is also associated with gingival and periodontal adverse reactions. Patients should maintain routine oral hygiene and regular dental checkups while taking it. Brushing, flossing, and dental visits are not glamorous, but neither is explaining to your dentist that your gums have been sending warning emails for three months.
Liver Test Changes
Clinical data noted liver function test elevations in some patients. This does not mean every patient will have liver problems, but it explains why clinicians may monitor blood work or ask about symptoms such as unusual fatigue, dark urine, yellowing of the skin or eyes, or persistent nausea.
Brinsupri Warnings and Precautions
Before taking Brinsupri, patients should tell their healthcare provider about all medical conditions, especially dental or gum problems, skin conditions, high blood pressure, liver problems, pregnancy, plans for pregnancy, breastfeeding, and upcoming surgery or dental procedures.
Live Vaccines
The use of live attenuated vaccines should be avoided during Brinsupri treatment unless a healthcare professional gives specific guidance. Patients should tell their provider they are taking Brinsupri before receiving any vaccine.
Pregnancy and Breastfeeding
There are no adequate human data to determine the risk of Brinsupri during pregnancy. Animal studies showed developmental findings at high exposures in rats, while rabbit data did not show adverse fetal effects at tested exposures. For breastfeeding, there are no data confirming whether brensocatib or its metabolites pass into human milk. Anyone pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with a clinician.
Pediatric and Older Adult Use
Brinsupri is approved for patients 12 years and older. Its safety and effectiveness have not been established in children under 12. Clinical studies included older adults, and no overall differences in safety or effectiveness were observed compared with younger adults, although individual health conditions still matter.
Brinsupri Drug Interactions
Patients should give their doctor and pharmacist a complete list of prescription drugs, over-the-counter medicines, vitamins, and supplements. Brensocatib is affected by pathways involving CYP3A and transporters such as P-gp and BCRP. Strong CYP3A4 and P-gp inhibitors, such as clarithromycin, can increase brensocatib exposure. Strong CYP3A4 inducers, such as rifampin, can lower exposure.
Acid-reducing therapy with esomeprazole did not meaningfully change brensocatib exposure in clinical pharmacology data. Even so, patients should not assume “no interaction” just because a medication is common. Grapefruit, herbal supplements, antibiotics, seizure medicines, antifungals, and heart medicines can all be relevant depending on the person’s medication list.
What to Discuss With Your Doctor Before Starting Brinsupri
A helpful pre-treatment conversation may include:
- How often bronchiectasis flares happen and how severe they are
- Current airway clearance routine
- History of skin conditions, gum disease, or dental procedures
- Blood pressure history
- Liver test history
- Current medications and supplements
- Vaccination plans
- Pregnancy or breastfeeding considerations
Patients should also ask what improvement would realistically look like. With chronic lung disease, success may mean fewer flares, longer time between flare-ups, fewer antibiotic courses, better daily stability, or less fear of the next respiratory setback. It may not feel like a Hollywood transformation scene with dramatic music, but fewer bad lung days can be a very big deal.
Brinsupri and Bronchiectasis Treatment Plans
Bronchiectasis management usually involves more than one strategy. Airway clearance techniques help move mucus. Antibiotics may treat bacterial exacerbations. Inhaled medicines may help selected patients. Exercise, hydration, pulmonary rehabilitation, vaccination planning, and infection monitoring may also play roles. Brinsupri adds a targeted anti-inflammatory approach for eligible patients with NCFB.
The most effective treatment plan is personalized. Two people can both have bronchiectasis and still have very different causes, infection patterns, symptoms, CT findings, sputum cultures, and treatment goals. That is why Brinsupri should be discussed with a clinician familiar with the patient’s lung history.
Patient Experience: Living With Brinsupri in Real Life
Starting a new medication for bronchiectasis can feel both hopeful and awkward. Hopeful, because Brinsupri represents a targeted option for a condition that has historically relied heavily on airway clearance, antibiotics, and symptom control. Awkward, because adding another daily medication means building a routine, watching for side effects, handling insurance questions, and remembering that “once daily” still requires the very human skill of not forgetting things while making breakfast.
Many patients with NCFB already live with a packed routine. Mornings may involve coughing, mucus clearance, inhalers or nebulizers, hydration, and checking whether today feels like a normal day or the opening credits of a flare. Adding Brinsupri may be easiest when it is tied to an existing habit, such as brushing teeth, eating breakfast, or using a pill organizer. The goal is not perfection; the goal is repeatable consistency.
A practical experience many patients may relate to is learning the difference between “normal for me” and “worth reporting.” A mild headache might be noted. A new rash, thickened skin, painful gums, loose teeth, or unusual mouth irritation should move higher on the priority list. Keeping a simple symptom journal can help. It does not need to be a dramatic medical diary with candlelight and classical music. A few notes on dates, symptoms, missed doses, blood pressure readings, dental symptoms, and flare signs can make follow-up appointments much more productive.
Dental care deserves special attention. Because Brinsupri carries warnings related to gum and periodontal issues, patients may want to schedule a dental checkup before or soon after starting therapy. Brushing and flossing regularly may sound basic, but basic is sometimes powerful. If gum tenderness, bleeding, tooth pain, mouth sores, or loose teeth appear, patients should contact a dentist or prescriber rather than waiting for the problem to “see itself out.” Teeth are famously bad at self-management.
Skin monitoring is another real-world habit. Patients may check for rash, cracking, peeling, thickened areas, persistent dryness, or unusual skin changes. Moisturizer may help ordinary dryness, but new or persistent skin findings should be discussed with a clinician. People with a history of skin cancer or suspicious lesions should be especially careful to ask their healthcare provider how they should be monitored.
Another common experience is expectation management. Brinsupri is not a rescue medicine, and patients may not “feel” it working after the first dose. Its value is measured over time, especially in flare frequency and disease stability. That can be frustrating because humans like instant feedback. Lungs, unfortunately, do not send push notifications saying, “Congratulations, inflammation pathway adjusted.” Regular follow-up helps determine whether the medication is doing what it is supposed to do.
Finally, patients should remember that Brinsupri does not erase the basics of bronchiectasis care. Airway clearance, sputum testing when needed, avoiding smoke exposure, staying current on non-live vaccines when recommended, exercising within medical limits, and seeking early care for worsening symptoms remain important. Brinsupri may be an important tool, but the toolbox still matters.
Conclusion
Brinsupri (brensocatib) is a once-daily prescription tablet for non-cystic fibrosis bronchiectasis in adults and children 12 years and older. As a DPP1 inhibitor, it targets neutrophil-driven inflammation involved in bronchiectasis flare-ups. Its key benefits include reducing pulmonary exacerbations and helping some patients experience longer periods without flares. Its key risks include skin reactions, gum and periodontal problems, possible blood pressure concerns, liver test changes, and vaccine precautions involving live attenuated vaccines.
For patients and families, the best approach is informed teamwork: understand the dose, know the tablet appearance, watch for side effects, protect dental and skin health, and keep open communication with the healthcare team. Brinsupri is not magic, but for eligible patients with NCFB, it may be a meaningful new chapter in managing a stubborn chronic lung condition.
